{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:50:39Z","timestamp":1770475839523,"version":"3.49.0"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"24","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Promoter hypermethylation is an alternative pathway for gene silencing in neoplastic cells and a promising cancer detection marker. Although quantitative methylation-specific PCR (QMSP) of the GSTP1 promoter has demonstrated near perfect specificity for cancer detection in prostate biopsies, we postulated that identification and characterization of additional methylation markers might further improve its high (80\u201390%) sensitivity.<\/jats:p>\n               <jats:p>Experimental Design: We surveyed nine gene promoters (GSTP1, MGMT, p14\/ARF, p16\/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 benign prostatic hyperplasias (BPH). The methylation levels were calculated and were correlated with clinical and pathologic indicators.<\/jats:p>\n               <jats:p>Results: Only the methylation frequencies of GSTP1 and APC were significantly higher in prostate carcinoma compared with BPH (P &amp;lt; 0.001). Methylation levels of GSTP1, APC, RASSF1A, and CRBP1, differed significantly between prostate carcinoma and HGPIN, and\/or HGPIN or BPH (P &amp;lt; 0.0001).With QMSP and empirically defined cutoff values, the combined use of GSTP1 and APC demonstrated a theoretical sensitivity of 98.3% for prostate carcinoma, with 100% specificity. Methylation levels were found to correlate with tumor grade (GSTP1 and APC) and stage (GSTP1, RASSF1A, and APC).<\/jats:p>\n               <jats:p>Conclusions: Our data demonstrate the existence of a progressive increase of promoter methylation levels of several cancer-related genes in prostate carcinogenesis, providing additional markers to augment molecular detection of prostate carcinoma. Because methylation levels of GSTP1, APC, and RASSF1A are associated with advanced grade and stage, QMSP might augment the pathologic indicators currently used to predict tumor aggressiveness.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-04-0894","type":"journal-article","created":{"date-parts":[[2005,9,22]],"date-time":"2005-09-22T00:01:11Z","timestamp":1127347271000},"page":"8472-8478","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":210,"title":["A Quantitative Promoter Methylation Profile of Prostate Cancer"],"prefix":"10.1158","volume":"10","author":[{"given":"Carmen","family":"Jero\u0301nimo","sequence":"first","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Departments of"},{"name":"2Genetics,"},{"name":"3Pathology, and"}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Departments of"},{"name":"3Pathology, and"}]},{"given":"Mohammad O.","family":"Hoque","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Departments of"}]},{"given":"Elizabeth","family":"Mambo","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Departments of"}]},{"given":"Franclim R.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"2Genetics,"}]},{"given":"Grac\u0327a","family":"Varzim","sequence":"additional","affiliation":[{"name":"2Genetics,"}]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[{"name":"4Urology, Portuguese Oncology Institute-Porto, Porto, Portugal"}]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"2Genetics,"}]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[{"name":"3Pathology, and"}]},{"given":"David","family":"Sidransky","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Departments of"}]}],"member":"1086","published-online":{"date-parts":[[2004,12,28]]},"reference":[{"key":"2023011320454833800_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Tiwari RC, Murray T, et al Cancer statistics 2004. CA Cancer J Clin\u20082004;54:8-29.","DOI":"10.3322\/canjclin.54.1.8"},{"key":"2023011320454833800_B2","doi-asserted-by":"crossref","unstructured":"Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer\u20081997;79:1370-80.","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1370::AID-CNCR15>3.0.CO;2-X"},{"key":"2023011320454833800_B3","doi-asserted-by":"crossref","unstructured":"Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am\u20082001;28:555-65.","DOI":"10.1016\/S0094-0143(05)70163-4"},{"key":"2023011320454833800_B4","doi-asserted-by":"crossref","unstructured":"Moinpour CM, Savage MJ, Troxel A, et al Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst (Bethesda)\u20081998;90:1537-44.","DOI":"10.1093\/jnci\/90.20.1537"},{"key":"2023011320454833800_B5","doi-asserted-by":"crossref","unstructured":"Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene\u20082002;21:5427-40.","DOI":"10.1038\/sj.onc.1205600"},{"key":"2023011320454833800_B6","doi-asserted-by":"crossref","unstructured":"Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer\u20082002;2:210-9.","DOI":"10.1038\/nrc755"},{"key":"2023011320454833800_B7","unstructured":"Maruyama R, Toyooka S, Toyooka KO, et al Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res\u20082002;8:514-9."},{"key":"2023011320454833800_B8","doi-asserted-by":"crossref","unstructured":"Yamanaka M, Watanabe M, Yamada Y, et al Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer\u20082003;106:382-7.","DOI":"10.1002\/ijc.11227"},{"key":"2023011320454833800_B9","doi-asserted-by":"crossref","unstructured":"Jero\u0301nimo C, Usadel H, Henrique R, et al Quantitation of GSTP1 hypermethylation distinguishes between non-neoplastic prostatic tissue and organ confined prostate adenocarcinoma. J Natl Cancer Inst (Bethesda)\u20082001;93:1747-52.","DOI":"10.1093\/jnci\/93.22.1747"},{"key":"2023011320454833800_B10","doi-asserted-by":"crossref","unstructured":"Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol\u20082003;169:1138-42.","DOI":"10.1097\/01.ju.0000049627.90307.4d"},{"key":"2023011320454833800_B11","doi-asserted-by":"crossref","unstructured":"Harden SV, Sanderson H, Goodman SN, et al Quantitative GSTP1 methylation improves the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst (Bethesda)\u20082003;95:1634-7.","DOI":"10.1093\/jnci\/djg082"},{"key":"2023011320454833800_B12","unstructured":"Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. Prostate   Hermanek P Hutter RVP Sobin LH Wagner G Wittekind C eds. . Illustrated guide to the TNM\/pTNM classification of malignant tumors\u20081997278-80.  Springer-Verlag Heidelberg, Germany"},{"key":"2023011320454833800_B13","doi-asserted-by":"crossref","unstructured":"Ahrendt SA, Chow JT, Xu LH, et al Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (Bethesda)\u20081999;91:332-9.","DOI":"10.1093\/jnci\/91.4.332"},{"key":"2023011320454833800_B14","doi-asserted-by":"crossref","unstructured":"Gleason DF, Mellinger GT. Veterans Administration Cooperative Urological Research group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol\u20081974;111:58-64.","DOI":"10.1016\/S0022-5347(17)59889-4"},{"key":"2023011320454833800_B15","doi-asserted-by":"crossref","unstructured":"Olek A, Oswald J, Walter JA. A modified and improved method of bisulfite based cytosine methylation analysis. Nucleic Acids Res\u20081996;24:5064-6.","DOI":"10.1093\/nar\/24.24.5064"},{"key":"2023011320454833800_B16","unstructured":"Harden SV, Tokumaru Y, Westra WH, et al Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res\u20082003;9:1370-5."},{"key":"2023011320454833800_B17","unstructured":"Usadel H, Brabender J, Danenberg KD, et al Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res\u20082002;62:371-5."},{"key":"2023011320454833800_B18","doi-asserted-by":"crossref","unstructured":"Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol\u20082002;160:605-12.","DOI":"10.1016\/S0002-9440(10)64880-8"},{"key":"2023011320454833800_B19","unstructured":"Eads CA, Lord RV, Wickramasinghe K, et al Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res\u20082001;61:3410-8."},{"key":"2023011320454833800_B20","doi-asserted-by":"crossref","unstructured":"Jarrard DF, Bova GS, Ewing CM, et al Deletional, mutational, and methylation analyses of CDKN2 (p16\/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer\u20081997;19:90-6.","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V"},{"key":"2023011320454833800_B21","doi-asserted-by":"crossref","unstructured":"Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene\u20082002;21:6835-40.","DOI":"10.1038\/sj.onc.1205814"},{"key":"2023011320454833800_B22","unstructured":"Kuzmin I, Gillespie JW, Protopopov A, et al The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res\u20082002;62:3498-502."},{"key":"2023011320454833800_B23","unstructured":"Virmani AK, Rathi A, Sathyanarayana UG, et al Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res\u20082001;7:1998-2004."},{"key":"2023011320454833800_B24","unstructured":"Virmani AK, Tsou JA, Siegmund KD, et al Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomark Prev\u20082002;11:291-7."},{"key":"2023011320454833800_B25","unstructured":"Esteller M, Guo M, Moreno V, et al Hypermethylation-associated inactivation of the cellular retinol-binding protein 1 gene in human cancer. Cancer Res\u20082002;62:5902-5."},{"key":"2023011320454833800_B26","unstructured":"Singal R, van Wert J, Bashambu M. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res\u20082001;61:4820-6."},{"key":"2023011320454833800_B27","doi-asserted-by":"crossref","unstructured":"Noguchi M, Stamey TA, McNeal JE, et al Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol\u20082003;170:459-63.","DOI":"10.1097\/01.ju.0000070928.49986.04"},{"key":"2023011320454833800_B28","doi-asserted-by":"crossref","unstructured":"Nakayama M, Bennett CJ, Hicks J, et al Hypermethylation of the human glutathione S-transferase pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate. Am J Pathol\u20082003;163:923-33.","DOI":"10.1016\/S0002-9440(10)63452-9"},{"key":"2023011320454833800_B29","doi-asserted-by":"crossref","unstructured":"Jero\u0301nimo C, Henrique R, Hoque MO, et al Quantitative RAR\u03b22 hypermethylation: a promising prostate cancer marker. Clin Cancer Res\u20082004;10:4010-4.","DOI":"10.1158\/1078-0432.CCR-03-0643"},{"key":"2023011320454833800_B30","doi-asserted-by":"crossref","unstructured":"Bostwick DG. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol\u20081996;30:145-52.","DOI":"10.1159\/000474164"},{"key":"2023011320454833800_B31","doi-asserted-by":"crossref","unstructured":"Foster CS, Bostwick DG, Bonkhoff H, et al Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol\u20082000;205(Suppl):19-43.","DOI":"10.1080\/003655900750169284"},{"key":"2023011320454833800_B32","doi-asserted-by":"crossref","unstructured":"Nelson WG, De Marzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology\u20082001;57(Suppl. 1):39-45.","DOI":"10.1016\/S0090-4295(00)00939-0"},{"key":"2023011320454833800_B33","doi-asserted-by":"crossref","unstructured":"Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA, Akslen LA. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer (Phila)\u20082000;88:416-24.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<416::AID-CNCR24>3.0.CO;2-#"},{"key":"2023011320454833800_B34","doi-asserted-by":"crossref","unstructured":"Guess HA. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev\u20082001;23:152-8.","DOI":"10.1093\/oxfordjournals.epirev.a000782"},{"key":"2023011320454833800_B35","doi-asserted-by":"crossref","unstructured":"Leav I, McNeal JE, Ho S-M, Jiang Z. \u03b1-Methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Hum Pathol\u20082003;34:228-33.","DOI":"10.1053\/hupa.2003.42"},{"key":"2023011320454833800_B36","doi-asserted-by":"crossref","unstructured":"Erbersdobler A, Huhle S, Palisaar J, et al Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone. Prostate Cancer Prostatic Dis\u20082002;5:279-84.","DOI":"10.1038\/sj.pcan.4500602"},{"key":"2023011320454833800_B37","doi-asserted-by":"crossref","unstructured":"Erbersdobler A, Fritz H, Schnoger S, et al Tumour grade, proliferation, apoptosis, microvessel density, p53 and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol\u20082002;41:40-6.","DOI":"10.1016\/S0302-2838(01)00021-5"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/24\/8472\/1923985\/zdf02404008472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/24\/8472\/1923985\/zdf02404008472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:31:25Z","timestamp":1673645485000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/10\/24\/8472\/168753\/A-Quantitative-Promoter-Methylation-Profile-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,15]]},"references-count":37,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2004,12,28]]},"published-print":{"date-parts":[[2004,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-0894","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,15]]}}}